A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01

2019148 citationsJournal Articlegold Open Access

Authors

ClinicalTrials.gov Identifier: NCT03363217 December 6, 2017.

Good health and well-being

Published in: BMC Cancer

Volume 19, Issue 1, pp. 1250-1250

Field-Weighted Citation Impact: 9.57